No Evidence of Tachyphylaxis with Chronic Tegoprazan Use
Tegoprazan does not cause tachyphylaxis (desensitization) with chronic use, unlike some other drug classes such as H2-receptor antagonists which are known to develop tolerance. This is a key advantage of potassium-competitive acid blockers (P-CABs) as a drug class.
Mechanism Supports Sustained Efficacy
The pharmacologic properties of tegoprazan actually argue against tachyphylaxis:
Reversible ionic binding: Tegoprazan binds reversibly to the potassium-binding site of H+-K+-ATPase, maintaining consistent acid suppression without the need for escalating doses 1
Long half-life (6-9 hours): This extended duration allows tegoprazan to continuously bind to proton pumps as they become active, providing sustained acid inhibition throughout the 24-hour period 1
Not a prodrug: Unlike PPIs, tegoprazan doesn't require acid activation, so its efficacy remains consistent regardless of intragastric pH changes that occur over time 1
Clinical Evidence from Long-Term Studies
The 2024 AGA guidelines specifically note that P-CABs like tegoprazan maintain their potent acid suppression over extended periods. In maintenance therapy studies extending to 260 weeks (5 years), vonoprazan (a related P-CAB) maintained consistent gastrin elevation and acid suppression without evidence of tolerance 1. While this data is from vonoprazan, the class mechanism suggests similar behavior for tegoprazan.
Recent clinical trials of tegoprazan demonstrate sustained efficacy without dose escalation requirements 2, 3, 4. The fact that fixed doses (50 mg and 100 mg) maintain therapeutic effect without needing upward titration over treatment courses is clinical evidence against tachyphylaxis.
Contrast with H2-Receptor Antagonists
This is fundamentally different from H2-receptor antagonists, which are well-documented to develop tachyphylaxis within days to weeks of continuous use. A 2025 pharmacovigilance study identified multiple drug classes associated with tachyphylaxis, but notably P-CABs were not among them 5.
Clinical Implications
- You can prescribe tegoprazan for long-term maintenance therapy without concern for loss of efficacy
- No need for drug holidays or dose escalation strategies
- Patients requiring chronic acid suppression can remain on stable doses
- The main consideration for long-term use is monitoring for elevated gastrin levels and potential fundic gland polyps (as with any potent acid suppressant), not loss of drug effect 1